2020

AUGUST 14, 2020

Found Karis Bio Inc.

Dr. Young-sup Yoon established company, Karis Bio Inc., using innovative cell-based therapy techniques for treatment of cardiovascular diseases.

AUGUST 15, 2020

Locate at Yonsei University Severance Hospital

Locate at Avison Biomedical Research Center, Rm 525, Yonsei-Ro  50-1, Seodaemun-Ku, Seoul, 03722, Republic of Korea

SEPTEMBER, 2020

Awarded U-Tech Valley Business by Korea Technology Finance Corporation

DECEMBER, 2020

Funded by Angel Investors

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2021

MAY, 2021

Received investments from major 5 Investors

Korea Development Bank, Premier Partners, Aju IB Investment, Seoul IP, Devsisters Ventures

Series A 103억원 투자유치

May 15, 2021

Karis Bio R&D center certified by Korea Industrial Technology Association

July 14, 2021

Venture Business certified by Korea Venture Business Association

August 15, 2021

Selected for the 2021 Material Component Technology Development Project by the Ministry of Trade, Industry and Energy (MOTIE), Korea

Karis Bio Inc. is the only organization selected in the Bio sector, as the lead agency of the 2021 Material Component Technology Project, supported by the Ministry of Trade, Industry and Energy (MOTIE) and managed by the Korea Institute for Advancement of Technology (KIAT). A total of KRW 2.6 billion is provided for research and development for three years.

September 16, 2021

Provided the world’s first proof for cardiac stem cell therapy in regenerative medicine

Nature Biomedical Engineering (IF: 26.671): Through a direct conversion method of fibroblasts, “directly reprogrammed cardiac-like tissue“ including major cardiac cells and extracellular matrix was generated and confirmed its therapeutic effect and heart regeneration in a mouse model.

October 20, 2021

“Good-Bio Award“ in the “Cell Therapy for Cardiovascular Disease” category

Karis Bio Inc. has won the “Good-Bio Award” in the “Cell Therapy for Cardiovascular Disease” category at the “7th Korea Good Company Awards 2021,“ hosted by Money Today.

November 1, 2021

Approved by the committee on the Advanced Regenerative Medicine Research under the Ministry of Health and Welfare

December 9, 2021

Dr. Young-sup, Yoon, the CEO of Karis Bio Inc., on the KBS 20th anniversary special program, called “Mysteries of the Human Body”

Dr. Young-sup, Yoon, CEO of Karis Bio Inc. and a cardiologist, scientist and professor in the Division of Cardiology, Emory University (USA), was interviewed on the TV show, Mysteries of the Human Body, to explain the Karis Bio’s technology that can help treat cardiovascular disease, the world’s leading cause of death.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2022

Jan 2, 2022

Established of Karis Bio USA in Atlanta, GA

May 13, 2022

Selected for a research project of Global Vaccine Leading Technology Center, supported by the Ministry of Health and Welfare, Korea

Karis Bio Inc. participates in the vaccine-based technology development project organized by the Global Vaccine Leading Technology Center under the Ministry of Health and Welfare, Korea.

May 20, 2022

Opened a Gasan branch office of Karis Bio Inc.

Karis Bio Inc. has established a branch office in the Seoul Digital Industrial Complex in Gasan-dong (Korea) and held an opening ceremony.

Sep 05, 2022

“Good-Bio Award“ for two consecutive years

‘Karis Bio Inc. was awarded the “Good-Bio Award” in the “Cell Therapy for Cardiovascular Disease” category for the second consecutive year at the “8th Korea Good Company Awards 2022.

Nov 02, 2022

Established a cGMP (cleanroom) facility

Karis Bio Inc. opened a cGMP facility in the Seoul Digital Industrial Complex in Korea, to manufacture the first domestic clinical trial of induced pluripotent stem cell (iPSC)-derived cell therapy products.

Dec 27, 2022

Selected for a Tech Investor Program for Scale-up (Scale-up TIPS)

Karis Bio Inc. is selected for the “2022 Investment-oriented R&D Scale-up TIPS“ project by the Ministry of SMEs and Startups.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2023

Jan 18, 2023

Series B financing

Series B fundraising (Korea Development Bank, Premier Partners, Aju IB Investment, Devsisters Ventures)

Apl 07, 2023

Received a grant for a Regenerative Medicine Technology Development Project from the Korean Fund for Regenerative Medicine (KFRM)

Karis Bio Inc. is collaborating with Yonsei University Office of Research Affairs and University-Industry Foundation (UIF) to jointly develop regenerative medicine technologies for a total of 33 months, from April 2023 to the end of 2025.

May 09, 2023

KarisBio, Inc. CEO Yoon Young-sup’s research team discovers new genes for cardiovascular regeneration

Mr. Yoon Young-sup’s, the CEO of Karis Bio, Inc. an innovative cardiovascular therapeutics development company, has led a research team that has identified the mechanism behind the decreased regenerative capacity of myocardial cells. They have also discovered a method to enhance the proliferative ability of myocardial cells, ultimately leading to cardiac regeneration.

JULY, 2023

Contracts with the Korea Disease Control and Prevention Agency

KarisBio has signed a contract with the Korea Disease Control and Prevention Agency (KDCA) for the research service project titled “Development of Cell-Based Artificial Blood (Red Blood Cells and Platelets) Manufacturing and Validation Platform Technology.“

August, 2023

Taking part in The Basic Cardiovascular Science Conference

The 2023 Asian Cardiovascular Symposium (ACS), organized by the Korean Cardiovascular Society and hosted by CEO Young-sup Yoon, took place in Boston.

August, 2023

“Good-Bio Award“ for three consecutive years

“KarisBio Inc. was endowed with the “Good-Bio Award” for the third consecutive year in the “Cell Therapy for Cardiovascular Disease” category at the “9th Korea Good Company Awards 2023.

August, 2023

Securing Series B funding of $ 725,000 from Korea Venture Investment Corp.

Dec, 2023

“Karis Santa Claus“ Social Charity Activity

KarisBio conducted charitable volunteer activities in collaboration with the Gwangmyeong Comprehensive Community Welfare Center, providing support for vulnerable populations.

Dec, 2023

Securing Series B funding of $ 362,500from Yonsei Biohealth Technology Holdings.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2024

Apl, 2024

Occupancy at the Boston C&D Incubation Center

Established an office in the Boston C&D Incubation Center as part of the “K-Blockbuster Global Expansion Project“ supported by the Korea Health Industry Development Institute (KHIDI).

Apl, 2024

Approval for the World’s First Clinical Trial of Induced Pluripotent Stem Cell-Derived Endothelial Cell Therapy for Peripheral Arterial Disease

(The clinical trial titled “Safety and Evaluation of Induced Pluripotent Stem Cell-Derived Endothelial Cell Transplantation Therapy for Peripheral Arterial Disease Patients“ has been approved by both the Ministry of Health and Welfare’s Advanced Regenerative Medicine and Advanced Biopharmaceuticals Evaluation Committee and the Ministry of Food and Drug Safety.)

Apl, 2024

The first domestic approval for the management of human iPSCs and iPSC-derived cells in South Korea

The first in South Korea to acquire the ‘Human Cell Management Business License’ for induced pluripotent stem cells (iPSC) from the Ministry of Food and Drug Safety.

Apl, 2024

Awarded the ‘Cross-Ministerial Regenerative Medicine Technology Development Project’

Apl, 2024

Awarded ‘the ‘Bio Research Data Validation Project’

Apl, 2024

Awarded ‘the research contract project from the National Health Institute under the Korea Disease Control and Prevention Agency.

Apl, 2024

Securing Series B funding of $ 725,000 from Yonsei Technology Holdings.

May, 2024

Participation in the ‘Bio Korea 2024’ Exhibition

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

Innovative Cell Therapy for Cardiovascular Disease